Response to Androgens and Androgen Receptor Antagonists in the Presence of Cytokines in Prostate Cancer

Simple Summary Prostate cancer is the most frequently diagnosed non-cutaneous tumor in men in the Western world. Therapy for non-organ confined prostate cancer includes anti-androgens such as bicalutamide, enzalutamide and darolutamide. The androgen receptor is expressed during tumor initiation and progression. Androgen receptor could be activated by interleukins, which are produced by blood cells and adjacent stroma. These cytokines may affect response of tumor cells to anti-androgenic drugs, which are commonly used in prostate cancer therapy. There are several experimental studies showing an effect of anti-cytokine therapies in prostate cancer. However, the clinical translation is limited and more clinical trials are needed to improve action of anti-androgens in prostate cells which are stimulated by cytokines. Abstract Non-steroidal anti-androgens have a major role in the treatment of non-localized prostate cancer. Interleukins are involved in the regulation of many cellular functions in prostate cancer and also modify cellular response to anti-androgens. A specific role of selected IL is presented in this review. IL-8 is a cytokine expressed in prostate cancer tissue and microenvironment and promotes proliferation and androgen receptor-mediated transcription. In contrast, IL-1 displays negative effects on expression of androgen receptor and its target genes. A subgroup of prostate cancers show neuroendocrine differentiation, which may be in part stimulated by androgen ablation. A similar effect was observed after treatment of cells with IL-10. Another cytokine which is implicated in regulation of androgenic response is IL-23, secreted by myeloid cells. Most studies on androgens and IL were carried out with IL-6, which acts through the signal transducer and activator of the transcription (STAT) factor pathway. IL-6 is implicated in resistance to enzalutamide. Activation of the STAT-3 pathway is associated with increased cellular stemness. IL-6 activation of the androgen receptor in some prostate cancers is associated with increased growth in vitro and in vivo. Molecules such as galiellalactone or niclosamide have an inhibitory effect on both androgen receptor and STAT-3 pathways.

[1]  A. Zoubeidi,et al.  Interleukin-10 Induces Expression of Neuroendocrine Markers and PDL1 in Prostate Cancer Cells , 2020, Prostate cancer.

[2]  R. Vrzal,et al.  Interleukin-23 Represses the Level of Cell Senescence Induced by the Androgen Receptor Antagonists Enzalutamide and Darolutamide in Castration-Resistant Prostate Cancer Cells , 2020, Hormones and Cancer.

[3]  M. Kanchwala,et al.  Chronic IL-1 exposure drives LNCaP cells to evolve androgen and AR independence , 2020, bioRxiv.

[4]  Sitao Wu,et al.  Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer , 2019, Science Translational Medicine.

[5]  M. Kanchwala,et al.  RELA is sufficient to mediate interleukin‐1 repression of androgen receptor expression and activity in an LNCaP disease progression model , 2019, The Prostate.

[6]  A. D. De Marzo,et al.  IL8 Expression Is Associated with Prostate Cancer Aggressiveness and Androgen Receptor Loss in Primary and Metastatic Prostate Cancer , 2019, Molecular Cancer Research.

[7]  F. Claessens,et al.  The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models , 2018, Molecular Cancer Therapeutics.

[8]  H. G. van der Poel,et al.  Loss of androgen receptor signaling in prostate cancer‐associated fibroblasts (CAFs) promotes CCL2‐ and CXCL8‐mediated cancer cell migration , 2018, Molecular oncology.

[9]  S. Barry,et al.  IL-23 secreted by myeloid cells drives castration-resistant prostate cancer , 2018, Nature.

[10]  M. Kanchwala,et al.  Identification of an IL‐1‐induced gene expression pattern in AR+ PCa cells that mimics the molecular phenotype of AR− PCa cells , 2018, The Prostate.

[11]  F. Hamdy,et al.  Sprouty2 loss‐induced IL6 drives castration‐resistant prostate cancer through scavenger receptor B1 , 2018, EMBO molecular medicine.

[12]  G. Peng,et al.  Blocking the Feedback Loop between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on Prostate Cancer , 2017, Clinical Cancer Research.

[13]  Jing Xu,et al.  Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT , 2017, Cell Death & Disease.

[14]  P. Nelson,et al.  Expression of STAT3 in Prostate Cancer Metastases. , 2017, European urology.

[15]  Xiaotao Li,et al.  Reciprocal androgen receptor/interleukin‐6 crosstalk drives oesophageal carcinoma progression and contributes to patient prognosis , 2017, The Journal of pathology.

[16]  L. Reis,et al.  Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth. , 2016, Urologic oncology.

[17]  G. Kristiansen,et al.  SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells , 2016, Molecular Cancer Research.

[18]  S. Duensing,et al.  IL-6 Overexpression in ERG-Positive Prostate Cancer Is Mediated by Prostaglandin Receptor EP2. , 2016, The American journal of pathology.

[19]  Yezi Zhu,et al.  Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3‐AR axis inhibition , 2015, The Prostate.

[20]  Hong-Chiang Chang,et al.  Anti‐androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals , 2015, Molecular oncology.

[21]  Z. Jia,et al.  Early Growth Response 3 regulates genes of inflammation and directly activates IL6 and IL8 expression in prostate cancer , 2015, British Journal of Cancer.

[22]  M. Farach-Carson,et al.  IL‐1β Induces p62/SQSTM1 and Represses Androgen Receptor Expression in Prostate Cancer Cells , 2014, Journal of cellular biochemistry.

[23]  Hua Yu,et al.  Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling. , 2014, Cancer research.

[24]  Yezi Zhu,et al.  Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells , 2014, The Prostate.

[25]  A. Zoubeidi,et al.  The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancer , 2013, Molecular and Cellular Endocrinology.

[26]  K. Kalland,et al.  Generation of prostate tumor-initiating cells is associated with elevation of reactive oxygen species and IL-6/STAT3 signaling. , 2013, Cancer research.

[27]  S. Yeh,et al.  Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling , 2013, Cell Death and Disease.

[28]  O. Witte,et al.  Interleukin-6 and Oncostatin-M Synergize with the PI3K/AKT Pathway to Promote Aggressive Prostate Malignancy in Mouse and Human Tissues , 2013, Molecular Cancer Research.

[29]  W. Gerald,et al.  Phosphorylation of the Androgen Receptor by PIM1 in Hormone Refractory Prostate Cancer , 2012, Oncogene.

[30]  P. Nelson,et al.  IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR , 2011, Oncogene.

[31]  H. Kung,et al.  Interleukin-6 Regulates Androgen Synthesis in Prostate Cancer Cells , 2009, Clinical Cancer Research.

[32]  Q. Tang,et al.  Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2 , 2009, Molecular Cancer Therapeutics.

[33]  Haojie Huang,et al.  A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells. , 2008, Cancer research.

[34]  P. Johnston,et al.  Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. , 2008, Carcinogenesis.

[35]  S. Araki,et al.  Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. , 2007, Cancer research.

[36]  P. Johnston,et al.  Interleukin-8 Signaling Promotes Translational Regulation of Cyclin D in Androgen-Independent Prostate Cancer Cells , 2007, Molecular Cancer Research.

[37]  H. Klocker,et al.  Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. , 1998, Cancer research.

[38]  Y. Oshika,et al.  P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.